The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

BACKGROUND: Approximately 70% of lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation of oncometabolite D-2-hydroxyglutarate (D-2-HG); this leads to epigenetic dysregulation, oncogenesis, and subsequent clonal expansion. DS-1001 is an oral brain-penet...

Descripción completa

Detalles Bibliográficos
Autores principales: Natsume, Atsushi, Arakawa, Yoshiki, Narita, Yoshitaka, Sugiyama, Kazuhiko, Hata, Nobuhiro, Muragaki, Yoshihiro, Shinojima, Naoki, Kumabe, Toshihiro, Saito, Ryuta, Motomura, Kazuya, Mineharu, Yohei, Miyakita, Yasuji, Yamasaki, Fumiyuki, Matsushita, Yuko, Ichimura, Koichi, Ito, Kazumi, Tachibana, Masaya, Kakurai, Yasuyuki, Okamoto, Naoko, Asahi, Takashi, Nishijima, Soichiro, Yamaguchi, Tomoyuki, Tsubouchi, Hiroshi, Nakamura, Hideo, Nishikawa, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925696/
https://www.ncbi.nlm.nih.gov/pubmed/35722822
http://dx.doi.org/10.1093/neuonc/noac155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925696/
https://www.ncbi.nlm.nih.gov/pubmed/35722822
http://dx.doi.org/10.1093/neuonc/noac155

Ejemplares similares